论文部分内容阅读
目的:观察和分析西妥昔单抗(cetux-imab)双周方案联合奥沙利铂(OXA)治疗晚期大肠癌的近期疗效和毒副反应。方法:26例晚期大肠癌患者接受西妥昔单抗500mg/m2,d1;奥沙利铂85mg/m2,d1;2周重复,为1个周期。结果:26例患者平均治疗7.2个周期。CR0例,PR8例,SD9例,PD9例。总有效率为30.8%,疾病控制率65.4%,中位疾病进展时间(TTP)为6个月,Fisher精确概率法分析PR组较SD组单纯肝转移比例高,SD组肝肺联合转移比例高。痤疮样皮疹和骨髓抑制为主要毒副反应,皮疹达80.7%,白细胞下降达76.9%,其次是胃肠道反应和周围神经毒性。结论:西妥昔单抗双周方案联合奥沙利铂治疗晚期大肠癌,有较好疗效,且方便、安全,毒副反应可耐受。
Objective: To observe and analyze the short-term curative effect and toxicity of cetux-imab combined with oxaliplatin (OXA) in the treatment of advanced colorectal cancer. Methods: 26 patients with advanced colorectal cancer received cetuximab 500mg / m2, d1; oxaliplatin 85mg / m2, d1; 2 weeks repeated for 1 cycle. RESULTS: Twenty-six patients underwent an average of 7.2 cycles of treatment. CR0 cases, PR8 cases, SD9 cases, PD9 cases. The total effective rate was 30.8%, the disease control rate was 65.4%, the median time to progression of disease (TTP) was 6 months. The Fisher exact test showed that the ratio of pure liver metastasis in PR group was higher than that in SD group, and that in SD group was high . Acne-like rashes and myelosuppression were the main toxicities with a rash of 80.7% and leukopenia of 76.9%, followed by gastrointestinal reactions and peripheral neurotoxicity. Conclusion: The combination of cetuximab and oxaliplatin in the treatment of advanced colorectal cancer has good curative effect and is convenient, safe and tolerable.